Cyrus Harmon
CIK: 0001831410
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Olema Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jul 24, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct12.5K shares at avg. $11.71$146K - Jul 23, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct12.5K shares at avg. $11.58$145K - Jun 18, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
29.5K shares- - Jan 20, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct10K shares at avg. $26.88$269K - Jan 14, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct3.5K shares at avg. $29.12$102K - Dec 22, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct2.9K shares at avg. $28.53$82K - Sep 18, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct10K shares at avg. $8.33$83K - Sep 18, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect3.1K shares at avg. $8.32$26K - Sep 16, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect1.9K shares at avg. $8.08$15K - Sep 16, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct10K shares at avg. $8.04$80K - Jun 11, 2025OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
24.2K shares- - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct8K shares at avg. $8.66$69K - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct179 shares at avg. $9.39$2K - Dec 10, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct8.3K shares at avg. $9.37$77K - Dec 9, 2024OLMA
Olema Pharmaceuticals, Inc.
Award(A)Direct29.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 24, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 12,500 | $11.71 | $146,425 | Direct |
| Jul 23, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 12,500 | $11.58 | $144,738 | Direct |
| Jun 18, 2026 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 29,500 | - | - | Direct |
| Jan 20, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 10,000 | $26.88 | $268,800 | Direct |
| Jan 14, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 3,489 | $29.12 | $101,600 | Direct |
| Dec 22, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 2,881 | $28.53 | $82,195 | Direct |
| Sep 18, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 10,000 | $8.33 | $83,300 | Direct |
| Sep 18, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 3,086 | $8.32 | $25,676 | Indirect |
| Sep 16, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 1,914 | $8.08 | $15,465 | Indirect |
| Sep 16, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 10,000 | $8.04 | $80,400 | Direct |
| Jun 11, 2025 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 24,150 | - | - | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 7,958 | $8.66 | $68,916 | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 179 | $9.39 | $1,681 | Direct |
| Dec 10, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 8,256 | $9.37 | $77,359 | Direct |
| Dec 9, 2024 | OLMA Olema Pharmaceuticals, Inc. | Award(A) | 29,250 | - | $0 | Direct |
1-15 of 15 transactions
About Harmon Cyrus
Harmon Cyrus (SEC CIK 0001831410) files insider reports with the SEC as Director of Olema Pharmaceuticals, Inc. (OLMA).
Signal8 holds 8 ownership filings by Harmon Cyrus, all Form 4s, filed between Dec 11, 2024 and Jul 27, 2026. Those filings report 15 transactions, from Dec 9, 2024 to Jul 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Harmon Cyrus's filings is in SAN FRANCISCO, CA.
Recent filings by Harmon Cyrus
- Jul 24, 2026: Open-market sale of OLMA shares (Form 4, code S).
- Jul 23, 2026: Open-market sale of OLMA shares (Form 4, code S).
- Jun 18, 2026: Grant or award of OLMA derivative securities (Form 4, code A).
- Jan 20, 2026: Open-market sale of OLMA shares (Form 4, code S).
- Jan 14, 2026: Open-market sale of OLMA shares (Form 4, code S).
Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)
- O'Byrne Jason, CHIEF FINANCIAL OFFICER
- BVF PARTNERS L P/IL, Director
- BUTITTA CYNTHIA M, Director
- Garland J. Scott, Director
- Hrustanovic Gorjan, Director
- CLARK IAN T, Director